Defeating Meningitis by 2030: the Need for Global Invasive Meningococcal Disease Surveillance and Prevention
IKEEP. Rob Heyderman, Christina Obiero, Brenda Kwambana-Adams, Marco Safadi . 04/22/21; 319146
 Rob Heyderman, Christina Obiero, Brenda Kwambana-Adams, Marco Safadi
Rob Heyderman, Christina Obiero, Brenda Kwambana-Adams, Marco Safadi
Contributions Biography
About this activity
Learning Objectives
This webinar is Open-Access (no login required) and it was hosted on April 22, 2020 9:00 am - 10:00 am EDT (GMT: 1pm - 2pm). An on-demand version will be available one hour after the webinar’s conclusion, and a post-produced version (with slide navigation) within 2 to 3 hours."
If you are unable to attend the live event, bookmark this link! A post-produced on-demand version (with slide navigation) will be available within the next few hours.

Defeating Meningitis by 2030: Global Invasive Meningococcal Disease Surveillance and Prevention
Chair and Discussion Moderator - Rob Heyderman
Co-Chair - Christina Obiero
Equitable and Sustainable Access to Vaccines By Brenda Kwambana-Adams
Atypical Presentation and the Impact of COVID-19 By Marco Safadi 

Your opinion matters to us! Please take 2 minutes after the session to answer a quick survey: 

Technical Settings
This Live Session is available on all latest browsers. For the best viewing experience, a high-speed internet connection is required.
If you have a problem getting access to the live webinar, please contact the technical crew at

Meningococcal meningitis is a devastating disease with high mortality and long-term sequelae even in successfully managed cases. Although the burden of disease is greatest in the meningitis belt of sub-Saharan Africa, meningitis is a world-wide threat. Recent epidemics in Liberia, Nigeria, Togo, Niger, Guinea, Kyrgyzstan, Fiji and Chile and the spread of some virulent strains across the world has emphasized the need for a global approach to surveillance and prevention.
In this session, experts will discuss the urgent need for improved monitoring of invasive meningococcal disease and sequelae globally, will discuss the use of whole genome sequencing, strain typing and rapid diagnostics to better understand outbreak epidemiology and burden of disease and will provide updates on the emergence of new clones and hypervirulent strains. They will review WHO’s recently released Defeating Meningitis by 2030 Global Roadmap and what it will take to make vaccines widely available in low- and middle-income countries. 
The clinical presentations of meningococcal disease can vary. Recent observations suggest that certain serogroups may present with atypical signs and symptoms such as acute gastrointestinal symptoms, septic arthritis, bacteremic pneumonia or severe upper respiratory infection. Experts will discuss atypical clinical presentations which can be associated with higher case fatality rates and misdiagnoses. The immediate and longer-term impact of COVID-19 on meningococcal disease and meningococcal vaccine schedules is currently unclear and needs to be determined. 

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies